© 2004 by European Society of Cardiology
Copyright © 2004, European Society of Cardiology
Suppression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with β2-glycoprotein I
aDepartment of Cardiology Tel Aviv Medical Center, Vascular Biogenics, Tel Aviv University, Israel
bVascular Biogenics, Or Yehuda, Israel
cResearch Unit of Autoimmune Diseases, Tel Hashomer, Israel
dThe Institute of Atherosclerosis and Lipid Research, Sheba Medical Center, Tel Hashomer, Israel
* Corresponding authors. Jacob George is to be contacted at Department of Cardiology Tel Aviv Medical Center, Vascular Biogenics, Tel Aviv University, Israel. Tel.: +972-3-5302940; fax: +972-3-5343521. Dror Harats, Institute of Lipid and Atherosclerosis Research Sheba Medical Center Tel-Hashomer 52621, Israel. Email address: jacobg{at}post.tau.ac.il dharats{at}post.tau.ac.il
Background: Atherosclerosis is considered analogous to chronic inflammatory diseases. Beta2-glycoprotein I (β2GPI) is a phospholipid binding protein shown to serve as a target for prothrombotic antiphospholipid antibodies. It has recently been demonstrated to drive an immune mediated reaction and enhance murine atherosclerosis. Oral tolerance is a method in which feeding a given antigen, downregulates the respective immune responses towards it, and attenuates concomitant organ specific disorders. Herein, we tested the hypothesis, that inhibiting cellular immunity to β2GPI would result in suppression of fatty streak formation in mice. Methods and results: LDL receptor deficient mice were fed different doses of human or bovine β2GPI or BSA and than switched to an atherogenic diet. To determine the effect of feeding on lymph node proliferative indices, separate groups of mice were fed β2GPI and then immunized with the respective antigen. Feeding either human or bovine β2GPI was effective in attenuating atherosclerosis as compared to control fed animals. Oral feeding with of β2GPI inhibited lymph node cell reactivity to β2GPI in mice immunized against the human protein. Oral tolerance was also capable of reducing reactivity to oxidized LDL in mice immunized against oxLDL. IL-4 and IL-10 production was upregulated in lymph node cells of β2GPI-tolerant mice immunized against β2GPI, upon priming with the respective protein. Conclusion: Thus, oral administration of β2GPI is an effective means of suppressing atherogenesis in mice and should further be investigated.
KEYWORDS Atherosclerosis; Oral tolerance; Immunology; Lymphocyte; β2GPI
Time for primary review 35 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Carvalho, R. Pereira, and Y. Shoenfeld Vaccination, atherosclerosis and systemic lupus erythematosus Lupus, November 1, 2009; 18(13): 1209 - 1212. [Abstract] [PDF]
|
|
|
|
 |
|
 G.H.M. van Puijvelde, T. van Es, E.J.A. van Wanrooij, K.L.L. Habets, P. de Vos, R. van der Zee, W. van Eden, Th. J.C. van Berkel, and J. Kuiper Induction of Oral Tolerance to HSP60 or an HSP60-Peptide Activates T Cell Regulation and Reduces Atherosclerosis Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2677 - 2683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mor, D. Planer, G. Luboshits, A. Afek, S. Metzger, T. Chajek-Shaul, G. Keren, and J. George Role of Naturally Occurring CD4+CD25+ Regulatory T Cells in Experimental Atherosclerosis Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 893 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mor, G. Luboshits, D. Planer, G. Keren, and J. George Altered status of CD4+CD25+ regulatory T cells in patients with acute coronary syndromes Eur. Heart J., November 1, 2006; 27(21): 2530 - 2537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.H.M. van Puijvelde, A.D. Hauer, P. de Vos, R. van den Heuvel, M.J.C. van Herwijnen, R. van der Zee, W. van Eden, T.J.C. van Berkel, and J. Kuiper Induction of Oral Tolerance to Oxidized Low-Density Lipoprotein Ameliorates Atherosclerosis Circulation, October 31, 2006; 114(18): 1968 - 1976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tincani, C. B. Rebaioli, M. Taglietti, and Y. Shoenfeld Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus Rheumatology, October 1, 2006; 45(suppl_4): iv8 - iv13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Tincani, C Biasini-Rebaioli, R Cattaneo, and P Riboldi Nonorgan specific autoantibodies and heart damage Lupus, September 1, 2005; 14(9): 656 - 659. [Abstract] [PDF]
|
|
|
|
|
|
E Toubi and Y Shoenfeld Predictive and protective autoimmunity in cardiovascular diseases: is vaccination therapy a reality? Lupus, September 1, 2005; 14(9): 665 - 669. [Abstract] [PDF]
|
|